These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8697049)

  • 1. Combined drug treatment of obesity.
    Atkinson RL; Blank RC; Loper JF; Schumacher D; Lutes RA
    Obes Res; 1995 Nov; 3 Suppl 4():497S-500S. PubMed ID: 8697049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity.
    Ryan DH
    Endocrine; 2000 Oct; 13(2):193-9. PubMed ID: 11186220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug-clinics. The hue and cry over central appetite suppressants!].
    Scheen AJ
    Rev Med Liege; 1997 Sep; 52(9):613-5. PubMed ID: 9441348
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.
    Whigham LD; Dhurandhar NV; Rahko PS; Atkinson RL
    Int J Obes (Lond); 2007 May; 31(5):850-7. PubMed ID: 17146452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity.
    Greenway F; Herber D; Raum W; Herber D; Morales S
    Obes Res; 1999 Jul; 7(4):370-8. PubMed ID: 10440593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical cost savings of treating obesity with weight loss medications.
    Greenway FL; Ryan DH; Bray GA; Rood JC; Tucker EW; Smith SR
    Obes Res; 1999 Nov; 7(6):523-31. PubMed ID: 10574509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term drug treatment of obesity in a private practice setting.
    Atkinson RL; Blank RC; Schumacher D; Dhurandhar NV; Ritch DL
    Obes Res; 1997 Nov; 5(6):578-86. PubMed ID: 9449143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial weight loss as a predictor of response to obesity drugs.
    Dhurandhar NV; Blank RC; Schumacher D; Atkinson RL
    Int J Obes Relat Metab Disord; 1999 Dec; 23(12):1333-6. PubMed ID: 10643693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenfluramine and phentermine.
    Howlin D
    Ann Intern Med; 2001 Nov; 135(9):840-1. PubMed ID: 11694113
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical studies with phenylpropanolamine: a metaanalysis.
    Greenway FL
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):203S-205S. PubMed ID: 1530830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological approaches to intervention.
    Guy-Grand B
    Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S22-4. PubMed ID: 9130037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current concepts in the pharmacological management of obesity.
    Carek PJ; Dickerson LM
    Drugs; 1999 Jun; 57(6):883-904. PubMed ID: 10400403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the pharmacotherapy of obesity.
    Cerulli J; Lomaestro BM; Malone M
    Ann Pharmacother; 1998 Jan; 32(1):88-102. PubMed ID: 9475827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bipolar depression associated with fenfluramine and phentermine.
    Zimmer JE; Gregory RJ
    J Clin Psychiatry; 1998 Jul; 59(7):383-4. PubMed ID: 9714271
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacologic therapies for obesity.
    Kaplan LM
    Gastroenterol Clin North Am; 2010 Mar; 39(1):69-79. PubMed ID: 20202580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in obesity management.
    Poston WS; Foreyt JP; Borrell L; Haddock CK
    South Med J; 1998 Aug; 91(8):710-20. PubMed ID: 9715214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.
    Astrup A; Lundsgaard C
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():29-34. PubMed ID: 9792479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of phentermine and fenfluramine on alcohol consumption and alcohol withdrawal seizures in rats.
    Halladay AK; Fisher H; Wagner GC
    Alcohol; 2000 Jan; 20(1):19-29. PubMed ID: 10680713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebral hemorrhage in a patient taking fenfluramine and phentermine for obesity.
    Wen PY; Feske SK; Teoh SK; Stieg PE
    Neurology; 1997 Aug; 49(2):632-3. PubMed ID: 9270617
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.